一线疗法!百济神州/安进在国内启动 DLL3/CD3 双抗新 III 期临床

Insight数据库
29 Jul

7 月 28 日,药物临床试验登记与信息公示平台显示,百济神州/安进登记了一项Tarlatamab(塔拉妥单抗)用于未经治疗的广泛期小细胞肺癌(ES-SCLC)患者的 III 期临床。截图来源:药物临床试验登记与信息公示平台这是一项III 期、开放性、多中心、随机研究(DeLLphi-312),旨在比较塔拉妥单抗、度伐利尤单抗、卡铂和依托泊苷与度伐利尤单抗、卡铂和依托泊苷一线治疗ES-SCLC 的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10